source
- Kodiak Sciences' Phase 3 eye drug data beats Regeneron’s Eylea, shares doubleKodiak Sciences reported that its two experimental treatments for macular degeneration met the primary endpoints in a Phase 3 trial that directly compared them with Regeneron’s Eylea. The data show…
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.